Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Newbury Pharmaceuticals AB's Dividend Yield % or its related term are showing as below:
FRA:P52's Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.96 * Ranked among companies with meaningful Dividend Yield % only.
Newbury Pharmaceuticals AB (FRA:P52) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:P52 vs ZTS, UTHR, VTRS: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newbury Pharmaceuticals AB Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Newbury Pharmaceuticals AB's Dividend Yield % falls into.
Newbury Pharmaceuticals AB (FRA:P52) has a Dividend Yield % of 0.00% as of Aug. 28, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Newbury Pharmaceuticals AB and its competitors. According to the industry distribution chart, Newbury Pharmaceuticals AB ranks #999999 out of 507 companies in the Drug Manufacturers industry.
Is Newbury Pharmaceuticals AB's Dividend Yield % too high?
Newbury Pharmaceuticals AB's current Dividend Yield % is 0.00%. Based on the distribution chart, Newbury Pharmaceuticals AB ranks #999999 out of 507 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Newbury Pharmaceuticals AB ranks #999999 out of 507 companies for Dividend Yield %. This places Newbury Pharmaceuticals AB in the lower half of its industry. The industry median Dividend Yield % is 1.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.96, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Newbury Pharmaceuticals AB and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newbury Pharmaceuticals AB's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Newbury Pharmaceuticals AB (FRA:P52) has a current Dividend Yield % of 0.00%. The stock's GF Value™ is €0.20, compared to a current price of €0.16 — trading 22.3% below its estimated fair value. The current Dividend Yield % is 0.00%. Newbury Pharmaceuticals AB's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (FRA:P52), the current Dividend Yield % is 0.00% as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newbury Pharmaceuticals AB (FRA:P52) Overvalued in 2026?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued.
The current stock price of €0.16 is trading 22.3% below its estimated GF Value™ of €0.20.
Key valuation signals for FRA:P52:
Dividend Yield %: 0.00%
GF Value™: €0.20 vs. price of €0.16 (22.3% below fair value)
No single metric tells the full story. See the FRA:P52 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
42GF Score
Get the complete analysis for FRA:P52
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:P52 has been successfully added to your 
